Zymeworks Inc. (NYSE:ZYME) Director Buys $273,904.76 in Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 19,748 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was purchased at an average price of $13.87 per share, for a total transaction of $273,904.76. Following the completion of the transaction, the director now directly owns 15,720,161 shares in the company, valued at approximately $218,038,633.07. The trade was a 0.13 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 15th, Ecor1 Capital, Llc purchased 39,029 shares of Zymeworks stock. The shares were purchased at an average cost of $14.01 per share, for a total transaction of $546,796.29.
• On Monday, January 13th, Ecor1 Capital, Llc acquired 74,125 shares of Zymeworks stock. The stock was purchased at an average price of $13.39 per share, with a total value of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc bought 204,098 shares of Zymeworks stock. The shares were acquired at an average price of $13.13 per share, for a total transaction of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc purchased 21,021 shares of Zymeworks stock. The shares were acquired at an average price of $14.07 per share, with a total value of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc acquired 157,880 shares of Zymeworks stock. The stock was acquired at an average price of $14.78 per share, for a total transaction of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc bought 58,988 shares of Zymeworks stock. The shares were acquired at an average cost of $14.47 per share, with a total value of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc purchased 11,958 shares of Zymeworks stock. The stock was bought at an average cost of $14.12 per share, for a total transaction of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc acquired 16,692 shares of Zymeworks stock. The shares were bought at an average cost of $14.38 per share, with a total value of $240,030.96.

Zymeworks Stock Up 1.0 %

Shares of ZYME stock opened at $14.82 on Friday. Zymeworks Inc. has a 12-month low of $7.97 and a 12-month high of $17.70. The firm has a fifty day moving average of $14.09 and a 200-day moving average of $12.78. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -9.88 and a beta of 1.10.

Zymeworks (NYSE:ZYME) last released its earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The firm had revenue of $16.00 million during the quarter, compared to analysts’ expectations of $17.90 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The company’s revenue was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.41) EPS. On average, equities analysts expect that Zymeworks Inc. will post -1.39 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on ZYME shares. Stifel Nicolaus raised their target price on Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, October 28th. HC Wainwright restated a “neutral” rating and set a $12.00 price objective on shares of Zymeworks in a report on Friday, November 22nd. JPMorgan Chase & Co. upgraded shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price on the stock in a report on Monday, December 16th. Leerink Partners raised shares of Zymeworks from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $10.00 to $25.00 in a report on Thursday, November 7th. Finally, Citigroup upped their price objective on shares of Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zymeworks presently has an average rating of “Moderate Buy” and an average price target of $19.17.

Institutional Investors Weigh In On Zymeworks

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers grew its stake in shares of Zymeworks by 9.0% during the 2nd quarter. Rhumbline Advisers now owns 86,912 shares of the company’s stock worth $740,000 after acquiring an additional 7,210 shares in the last quarter. Victory Capital Management Inc. grew its position in Zymeworks by 23.5% in the second quarter. Victory Capital Management Inc. now owns 58,300 shares of the company’s stock valued at $496,000 after purchasing an additional 11,100 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in Zymeworks in the 2nd quarter valued at $696,000. Dimensional Fund Advisors LP lifted its position in Zymeworks by 127.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 715,632 shares of the company’s stock worth $6,090,000 after buying an additional 401,068 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Zymeworks by 104.8% during the 2nd quarter. Renaissance Technologies LLC now owns 236,781 shares of the company’s stock worth $2,015,000 after buying an additional 121,181 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.